DNA-coated gold nanoparticles for tracking hepatocyte growth factor secreted by transplanted mesenchymal stem cells in pulmonary fibrosis therapy. (13th December 2021)

• Record Type: Journal Article
• Authors: Bao, Hongying; Li, Yuxuan; Yu, Chenggong; Li, Xiaodi; Wang, Yujie; Gao, Li; Huang, Jie; Zhang, Zhijun
• Is Part Of: Biomaterials science. Volume 10:Number 2(2022)
• Page Start: 368
• Page End: 375
• Publication Date: 2021-12-13
• Subjects: Biomedical materials -- Periodicals; 610.28
• DOI: 10.1039/d1bm01362a
• Languages: English
• ISSNs: 2047-4830

Abstract

Abstract : Based on the fluorescence off–on principle, a dye-labeled Au nanoflare tracer is presented for in vivo tracking the secretion of hepatocyte growth factor (HGF) by MSCs during idiopathic pulmonary fibrosis (IPF) therapy. Abstract : The identification of paracrine factors secreted by transplanted mesenchymal stem cells (MSCs) during the treatment of idiopathic pulmonary fibrosis (IPF) is essential for understanding the role of MSCs in therapy. Herein, we report a facile and efficient strategy for in vivo tracking the secretion of hepatocyte growth factor (HGF) in MSCs during IPF therapy. In our strategy, a novel nanoflare tracer consisting of gold nanoparticles (AuNPs), complementary sequences and dye-labeled recognition sequences is developed. Briefly, the AuNPs are functionalized with oligonucleotide complementary sequences hybridized to the organic dye-labeled recognition sequences, where the organic fluorophores are in close proximity to the AuNPs. In the absence of targets, the dye and AuNPs are separated from each other, inducing the quenching of the fluorescence signal. However, in the presence of targets, the recognition sequences gradually fall off from the AuNPs, causing the fluorescence signal to rise. In brief, in vivo monitoring of the dynamic expression of HGF mRNA in transplanted MSCs during IPF therapy in the current work may provide new insight into the paracrine process of the transplanted MSCs, thereby advancing the MSC-based IPF therapy toward clinical applications.